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Abstract 
Aim: The new classification of breast cancer is based on microarray studies. Within the estrogen receptor 
(ER) positive breast carcinoma subtype further subgroups could be identified. In the present study, we 
analyzed the Her2 negative, highly proliferative subgroup (Luminal B1-like, LUMB1) with emphasis on their 
clinicopathological characteristics and progesterone receptor (PR) expression.  
Patients and methods: Our retrospective study concerned the period between 2000 and 2010. 158 
patients were selected with ER positive, Her2 negative, Ki67>15% breast cancer. The pathological and 
clinical data were collected and analyzed. Age, tumor grade and stage, ER, PR, Her2 and Ki67 expression 
were recorded. The clinicopathological variables were correlated to PR expression.  
Results: The mean age of the patients was 57.5 (28-75) years. The ratio of patients younger than 40, was 
8.86%. Shorter metastasis-free survival was observed in this young age group (P=0.044). The majority of 
our cases belonged to the pT1-pT2 stages (41.28% and 44.95%, respectively) whereas pT3 and T4 stage 
was detected in 5.50% and 8.25% of the cases, respectively. Almost half of the cases had no axillary lymph 
node metastasis (pN0: 48.91%), 1-3 lymph node metastases were detected in 38.04% (pN1), 4-10 
metastatic lymph nodes were identified in 9.78% (pN2) and pN3 stage was found in 3.26% of the cases.  
Most commonly the tumors were either grade 2 or 3 (44.16% and 45%, respectively). The median value of 
Ki67 labeling index was 30%. Disease progression was detected in 36.19% of the patients. According to PR 
expression, a tendency to better  prognosis (i.e. longer disease free- and overall survival) was detected in 
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cases showing >10% PR positivity. However, no difference was found regarding tumor size, axillary stage, 
grade and age when comparing lower and higher PR expressing tumors.  
Conclusions: LUMB1 breast carcinomas are typically grade 2 and grade 3, the Ki67 labeling index is often 
30% or higher. Distant metastases occur in more than one third of the cases. Within this subgroup, those 
cases with low PR expression represent a poor prognostic cohort. These findings require further 
investigations in larger number of LUMB1 breast cancer cases.   
Introduction
One of the reasons behind the heterogeneity of 
breast cancer is the phenotypical reflection of 
their different gene expression profiles. Cancers 
with different expression profiles show different 
clinical and prognostic features. Since the advent 
of microarray based classifications, various 
molecular classes of breast cancer have been 
described. The first and most robust molecular 
classification was published in 2000, when Perou 
and his group published their work on cDNA 
microarray studies of human breast cancers and 
described five major subtypes [24]. Hormone 
receptor positive breast cancers are treated with 
endocrine therapy. Although, in the majority of 
patients the likelihood of recurrence and disease 
related death decreased considerably due to 
administration of endocrine therapy, a number of 
patients are not responding or develop resistence 
to the treatment with time and therefore have a 
poorer prognosis. [1, 2]. It was, thus, a logical 
conclusion that there are subclasses within the 
group of ER positive breast cancers. Sorlie and co-
workers [3] classified the ER-positive breast 
cancers into Luminal A, B and C subgroups. 
Expression of ERα was highest in Luminal A 
cancers. Expression of ER regulated genes were 
lower in Luminal B és C subgroups. Most recently, 
the St. Gallen International Consensus 
Conference [4-8] suggested the following 
definitions for subclassifying breast cancers based 
on estrogen (ER), progesterone receptor (PR), 
Her2 and Ki67 protein expression. Luminal A-like 
(LUMA): ER-positive and PR-positive, low Ki67 
index, Her2-negative, "recurrence risk" low, Her2-
negative Luminal B-like (LUMB1): ER-positive and 
Her2-negative, and at least one of the followings: 
high Ki67, PR-negative/low, "recurrence risk" 
high; Her2-positive Luminal B-like (LUMB2): ER-
positive and Her2-positive, any PR, any Ki67, 
Her2-positive (non Luminal): ER-negative, PR-
negative, Her2-positive, Triple-negative: ER-
negative, PR-negative, Her2-negative.  
The prognostic and possible predictive role of low 
PR expression has been studied more recently. 
Within the luminal group of breast cancers, low 
expression of PR characterizes a more agressive, 
less endocrine therapy sensitive subgroup: lower 
ER levels, higher proliferation rate, larger tumor 
size, more positive axillary lymph nodes, 
aneuploid DNA content and increased expression 
of epidermal growth factor receptor were found 
[9]. Cancello and co-workers [10] investigated the 
role of PR in relation with recurrence in Lumial B 
breast cancers, considered a less favourable 
prognostic group. They divided the Luminal B 
breast cancers into 4 subgroups based on Her2 
and PR expression: ER+/PR+/Her2-; ER+/PR-
/Her2-; ER+/PR-/Her2+ és ER+/PR+/Her2+. They 
concluded that in both the Her2 positive and 
Her2 negative groups, low expression or lack of 
PR is related to shorter metastasis-free- and 
overall survival. Considering the difficulties in 
treating Luminal B breast cancers, many ongoing 
research aim at identifying newer targets for 
therapy. In our present study, we investigated 
LUMB1 breast carcinoma cases from the point of 
view of PR expression, among others. We 
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compared the level of PR expression with clinico-
pathological and follow-up data.  
Patients and methods 
ER-positive, Her2-negative breast carcinoma 
cases with Ki67 index ≥15% diagnosed between 
the period 2000-2010 were selected and the 
clinico-pathological data were collected. Follow-
up data of the patients were retrieved from the 
University’s database (MedSolution), the 
pathological data were collected from the files of 
the 2nd Department of Pathology following 
approval by the Institutional Review Board (SE-
IKEB 77/2007). Overall survival data were 
provided by the Central Office for Administrative 
and Electronic Public Services. In our study we 
considered age of the patients, grade, TNM stage, 
ER, PR, Her2 and Ki67 expression of the tumors. 
Age groups were created according to patient’s 
age at the time of the primary diagnosis of breast 
cancer. In order to elucidate the suspected 
prognostic significance of age at the primary 
diagnosis, we analyzed distant metastasis-free 
survival data at 35, 40 and 45 age thresholds. 
Tumor grade was defined according to the 
Nottingham grading system [11], TNM stage was 
recorded according to the 7th Edition of the 
American Joint Committee on Cancer and the 
International Union for Cancer Control (AJCC-
UICC) manual [12]. We calculated the distant 
metastasis-free survival (DMFS) as the period in 
months elapsed between the diagnosis of the 
primary tumor and the occurance of the first 
distant metastasis. Overall survival (OS) was also 
calculated in months: time elapsed between the 
diagnosis of the primary tumor to the time of 
disease related death. In some cases, in the 
cohort not all of the clinical or pathology data 
were available, but we didn’t exclude these cases 
from the statistical analyses upon this fact had no 
interference with the result of the calculation. 
Details of the immunohistochemical reactions for 
ER, PgR, Her2 and Ki67 are summarized in Table 
1.  
Table 1. Antibodies, dilutions and providers used 
in the study 
Antigen Provider Clone Dilution 
ER Novocastra 6F11 1:200 
PgR Novocastra 312 1:200 
HER2 Novocastra CB11 1:150 
Ki67 DAKO MIB1 1:100 
 
Hormone receptor positivity was recorded if >1% 
of the tumor cells showed positive nuclear 
reaction, in line with the ASCO/CAP guideline 
[25]. Concerning PR status we divided our cases 
into „PR low” and „PR high” subgroups. Since 
only scattered recent literature data are available 
regarding the prognostic meaning of low PR 
expression in breast cancer, we tested our cases 
at 5, 10 and 20% limits of PR expression. Ki67 
labeling index was estimated by eye-balling on a 
representative tumor slide. Any intensity of 
positive reaction was considered and the 
percentage of positive tumor cells was recorded. 
Her2 status was defined according to the 
ASCO/CAP recommendations valid at the time of 
the period under investigation [13, 26]. The study 
group comprised of 158 patients.  
For survival analysis Kaplan-Meier method was 
used; log-rank statistics was used to characterize 
the differences between prognostic groups. 
Categorical data were analysed using Chi-square 
test and Fischer exact test. Results were regarded 
statistically significant at p<0.05. Statistica 11.0 
software was used for each analysis (StatSoft, 
Tulsa, OK, USA).  
Results 
Clinical and pathological characteristics of the 
cases are shown in Table 2.  
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Table 2. Clinical and pathological characteristics 
of LUMB1 cancers included in this study 
Parameters N                       % 
T1 45 41,28% 
T2 49 44,95% 
T3 6 5,50% 
T4 9 8,25% 
No data 29  
N0 45 48,91% 
N1 35 38,04% 
N2 9 9,78% 
N3 3 3,26% 
No data 46  
Grade 1 13 10,83% 
Grade 2 53 44,16% 
Grade 3 54 45% 
No data 18 41,28% 
Treatment:   
Endocrine-and/or 
Chemotherapy 
105 84% 
Neoadjuvant therapy 20 16% 
No data 33  
Age   
<45  26 16,45% 
>45  132 83,54% 
Total 158  
 
Mean age of the patient at the time of the 
primary diagnosis was 57.51 (range: 25-75). 
Twenty six of 158 patients (16.45%) were <45, 
14/158 (8.86%) were <40 and 5/158 (3.16%) were 
<35 years. Age, as an adverse prognostic factor 
was significant regarding DMFS in patients <40 
when compared to DMFS of patients >40 
(p=0.044) (Figure 1). 
 
Figure 1. Distant metastasis-free survival 
according to patients’ age (p=0.044). 
We had treatment data from 125/158 patients. 
Neoadjuvant oncological treatment was used in 
20/125 cases (16%). In these patients, ER, PR, 
Ki67, Her2 immunohistochemistry results of the 
core biopsies were considered, while pT and pN 
stage was known from the surgical resection 
specimens. These cases were not considered 
further in the statistical analyses: we analysed 
data of 138 patients. 
Tumor size was known in 109/138 cases. The 
majority of the known cases belonged to the pT1 
and pT2 stage category (41.28% and 44.95% 
respectively), 5.50% were pT3. pT4 cases occured 
in 8.25%. Regarding axillary lymph nodes we 
could identify 92/138 cases with known regional 
lymph node status. Negative axillary lymph nodes 
were present in 48.91% of the cases, 1-3 
metastatic lymph nodes were recorded in 
38.04%, more than 10 metastatic lymph nodes 
were present in 9.78% and pN3 was diagnosed in 
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3.26% of the cases. Tumor grade was known in 
120 cases. The majority of the cancers were of 
grade 2 or grade 3 (53/120, 44.16% and 54/120, 
45%, respectively). The median Ki67 labeling 
index was 30%.  
In the adjuvant treated patient group we had 
follow up data in 105/138 patients. During the 
period examined 38/105 (36.19%) patients 
developed distant metastasis, among them 21 
patients (55.27%) presented with dissemination 
to multiple organs. More than half of the solitary 
metastases (52.94%) localized to the skeletal 
system.  
Relationship between PR expression 
and prognostic factors  
Clinical and pathological variables were analyzed 
in relation to PR expression. Since there are few 
data related to the exact role of PR positivity and 
its extent, we performed analyses with different 
cutpoints at 5, 10 and 20% PR positivity. Very low 
PR expression (0-5%) was detected in 53 cases 
(38.40%), 59 cases showed 0-10% PR positive 
tumor cells, and 69 cases (50%) had 0-20% PR 
positivity.  
When considering all cases, including the 20 core 
biopsies, the number of cases in the above three 
PR expression categories was the following: 63 
cases (39.87%) 0-5% PR positive tumor cells, 71 
cases (44.93%) 0-10% PR positive tumor cells, 73 
cases (46.20%) 0-20% PR positive tumor cells. In 
our cohort, the cutpoint of PR positivity that 
divided the patients into a better and a worse 
prognosis group was at 10%, but only at the level 
of tendency: cancers that have >10% PR positive 
cell population show better DMFS (p=0.07) 
(Figure 2). Regarding age groups, pT categories, 
tumor grade categories and pN categories, lower 
and higher (0-10% vs. >10%) PR expressing 
tumors didn’t show any specific distribution. 
(p=0.661, p=0.061, p=0.541, p=0.403, 
respectively). 
 
Figure 2. Distant metastasis-free survival 
according to PR expression at 10% positivity cut-
off (p=0.07). A tendency of shorter survival could 
be detected in low-PR expressing tumors. 
Discussion 
According to our results, grade 2 and grade 3 
cases predominate within the group of Luminal 
B1 breast cancers. Similar to these results, Park et 
al. found that among Luminal B subtype breast 
cancers, higher grade tumors are more common 
[14]. Many recent studies aim at clarifying the 
exact prognostic significance of Ki67 labeling 
index, although the cut-off value has been a 
subject of discussion: some authors use 10%, 
14%, or 20%, yet others suggest the use of the 
mean or median percentage of Ki67 positive 
tumor cells as threshold [15]. Despite the 
reported inter-observer differences in evaluating 
Ki67 labeling index, it is obvious that higher Ki67 
labeling index predicts poorer prognosis. 
Azambuja and co-workers [16] in a large meta-
analysis using 68 studies confirmed the higher 
risk of relapse and shorter survival in cases with 
higher Ki67 labeling index. Cheang and co-
workers [15] identified 13,25% Ki67 labeling 
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index as cut-off value for the differentiation of 
Luminal A from Luminal B breast cancers. The 
median value of Ki67 labeling index in  ER-
positive, Her2-negative breast cancer cases was 
14% in a multicenter study performed by Cserni 
and his group [17], but no subtyping of luminal 
cases was performed. In our present study, we 
used the 15% cut-off as it was also shown in a 
study by Cserni and co-workers that 
approximation of the value of Ki67 labeling index 
to the closest 0 or 5 is an adequate approach 
[17]. 
In our study group of Luminal B1 breast cancer 
cases the median value of Ki67 labeling index was 
30%. 
In our patient cohort, more than half (52.94%) of 
the solitary metastases occured in the skeletal 
system. Kennecke and co-workers [18] by 
studying the metastatic pattern of the different 
molecular subtypes found that in Luminal B 
breast cancers the most common distant 
metastatic site was in bones. More recently even 
more studies are focused on the significance of 
PR expression that show increased activity 
between ER and Her2 pathways behind low PR 
expression. The interaction between ER and Her2 
pathways probably downregulates PR [19]. 
However, there is no consensus in the literature 
regarding the cut point of relevant PR expression 
level. Prat and co-workers, based on statistical 
calculations, defined 20% PR positivity as relevant 
[20]. In our study, we found that at 10% cut-off of 
PR expression, a tendency of longer DMFS 
occured in those patients having >10% PR 
positivity in the primary tumor. Bardou and co-
workers reported longer 5-year survival in 
ER+/PR+ tumors (82,5%) than in  ER+/PR- 
tumors (73,8%). The same tendency was 
observed regarding OS. In multivariate analysis, 
the relative risk of relapse and disease related 
death was lower in ER+/PR+ and  ER+/PR- 
tumors than in ER-/PgR- tumors. However, they 
only could show a tendency and not statistically 
significant difference between ER+/PR+ and 
ER+/PR- tumors. [21].  
Ciriello and co-workers in 2013 [22], by 
investigating a large cohort of Luminal A breast 
cancers by means of genetic profiling found at 
least 4 prognostically different subtypes within 
the Luminal A subgroup. The prognosis of LUMB1 
cancers is regarded poor by many studies’ results, 
therefore any feature that could help to identify a 
better and a poorer prognostic subgroup could be 
clinically relevant (9, 15). According to one study, 
mutation of the TP53 gene is an independent 
adverse prognostic factor in Luminal B type 
breast cancer [23]. According to the results of our 
present study LUMB1 breast cancers show poor 
prognostic features (the vast majority belongs to 
grade 2 or 3 category, one third develops distant 
metastasis, the median Ki67 labeling index is 
high). These adverse features must encourage 
further research of this group of breast cancer. 
LUMB1 breast cancers expressing low levels of PR 
probably represent a poor prognostic group, that 
could be proved in much larger cohorts of breast 
cancer patients. Identification of poorer 
prognosis in hormone receptor positive breast 
carcinoma cases may allow more effective 
oncological approaches.  
Conclusions 
LUMB1 breast carcinomas are mainly grade 2 and 
grade 3, the Ki67 labeling index is often 30% or 
higher. Distant metastases occur in more than 
one third of the cases. Within this subgroup of 
breast carcinoma, those cases with low PR 
expression represent a poorer prognostic cohort 
presenting with shorter distant metastasis free 
survival. Further investigations are necessary in 
larger number of LUMB1 breast cancer cases to 
elucidate the exact role of PR lacking or low level 
expression in this subgroup of breast cancer. 
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